OS Therapies Incorporated
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $72.5M
- Price
- $1.55
- % Change (Daily % change from the live per-ticker quote feed.)
- +4.03%
- Volume
- 586.7K
About
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
Quick stats
Shares outstanding46.8M
Computed float43.8M
Float / shares93.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001795091
Websitehttps://ostherapies.com
AI Summary
AI-generated1/37
minorbullishregulatory
OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma
OS Therapies' subsidiary OS Animal Health received USDA feedback on its conditional licensure pathway for OST-HER2 in canine osteosarcoma, covering efficacy, safety, non-clinical, and CMC requirements.
OSAH plans to seek conditional licensure on existing clinical data and hopes for a 2027 U.S. commercial launch, though full licensure will require additional studies.
The company is also evaluating strategic and capital alternatives for OSAH, including a Q4 2026 crowdfunding intended to help the subsidiary meet U.S. exchange listing standards.
Red flags
- Full USDA licensure still requires additional clinical studies
- OSAH spinoff/monetization uncertain -- company states no assurance any IPO, listing, crowdfunding or spinoff will occur
- Planned OSAH crowdfunding could signal capital needs; parent is a clinical-stage company with pipeline funding demands